Emmaus Life SciencesEMMA -16.67% Median PS Value is $0.43 as of Jun. 26, 2026, which is 975% above its 10-year median of 0.04. The stock has 6 warning signs investors should review. Among 276 Biotechnology companies, Emmaus Life Sciences ranks better than 98.91% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Emmaus Life Sciences's Median PS Value or its related term are showing as below:
EMMA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.1
Current: 0.02
During the past 13 years, the highest Price to Median PS Value of Emmaus Life Sciences was 0.10. The lowest was 0.01. And the median was 0.04.
EMMA's Price-to-Median-PS-Value is ranked better than 98.91% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs EMMA: 0.02
Emmaus Life Sciences (OTCPK:EMMA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Emmaus Life Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.01
/
0.43
=
0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Median PS Value Related Terms
Emmaus Life Sciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs CERO, AGTX, WINT: Median PS Value Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.3243.
Emmaus Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.185.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Median PS Value of $0.43 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Emmaus Life Sciences and its competitors. This is 975% above median its historical median of 0.04. Over the past decade, Emmaus Life Sciences' Median PS Value has ranged from 0.01 to 0.10. According to the industry distribution chart, Emmaus Life Sciences ranks #3 out of 276 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Emmaus Life Sciences' Median PS Value too high?
Emmaus Life Sciences' current Median PS Value of $0.43 is 975% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.10. The Biotechnology industry median Median PS Value is 0.62. Emmaus Life Sciences' value of $0.43 is 30.6% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #3 out of 276 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' Median PS Value compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #3 out of 276 companies for Median PS Value. This places Emmaus Life Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.62. Emmaus Life Sciences' value of $0.43 is 30.6% below this benchmark. Historically, Emmaus Life Sciences' own Median PS Value has ranged from 0.01 to 0.10 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.62, Emmaus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Median PS Value of $0.43 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Median PS Value is $0.43, which is 975% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Median PS Value is $0.43, which is 975% above median its 10-year median of 0.04 and 30.6% below the Biotechnology industry median of 0.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Median PS Value is $0.43 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 